CO₂ Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial.

ABSTRACT:

Objectives

We aimed to study the efficacy of fractional CO₂ laser for genitourinary syndrome of menopause (GSM) symptoms in breast cancer (BC) survivors through a randomized, sham-controlled study, followed by an open-phase study assessing the impact of additional treatments.

Methods

BC survivors with GSM were randomized to receive either three sessions of intravaginal CO₂ laser or sham treatment every 3-4 weeks. The laser's energy was 45-60 mJ/pixel. Outcomes were compared one month following the last session. Participants initially receiving laser treatment were offered three more sessions, while those receiving sham had six laser sessions in an open-label study.

Results

Thirty-four BC survivors were randomized to laser (n = 19) or sham (n = 15

SUBMITTER: Jaber S 

PROVIDER: S-EPMC11988059 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature